BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ali AK, Watson DE. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies. Pharmacotherapy 2017;37:1383-90. [PMID: 28950039 DOI: 10.1002/phar.2035] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Miller ED, Abu-sbeih H, Styskel B, Nogueras Gonzalez GM, Blechacz B, Naing A, Chalasani N. Clinical Characteristics and Adverse Impact of Hepatotoxicity due to Immune Checkpoint Inhibitors. Am J Gastroenterol 2020;115:251-61. [DOI: 10.14309/ajg.0000000000000398] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
2 Chen G, Qin Y, Fan QQ, Zhao B, Mei D, Li XM. Renal adverse effects following the use of different immune checkpoint inhibitor regimens: A real-world pharmacoepidemiology study of post-marketing surveillance data. Cancer Med 2020;9:6576-85. [PMID: 32720449 DOI: 10.1002/cam4.3198] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Suresh K, Naidoo J, Lin CT, Danoff S. Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities. Chest 2018;154:1416-23. [PMID: 30189190 DOI: 10.1016/j.chest.2018.08.1048] [Cited by in Crossref: 73] [Cited by in F6Publishing: 81] [Article Influence: 18.3] [Reference Citation Analysis]
4 Raschi E, Mazzarella A, Antonazzo IC, Bendinelli N, Forcesi E, Tuccori M, Moretti U, Poluzzi E, De Ponti F. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities from Disproportionality Analysis of the FDA Adverse Event Reporting System. Target Oncol. 2019;14:205-221. [PMID: 30927173 DOI: 10.1007/s11523-019-00632-w] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 19.5] [Reference Citation Analysis]
5 Fan Q, Hu Y, Yang C, Zhao B. Myocarditis following the use of different immune checkpoint inhibitor regimens: A real-world analysis of post-marketing surveillance data. Int Immunopharmacol 2019;76:105866. [PMID: 31491729 DOI: 10.1016/j.intimp.2019.105866] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
6 Deligiorgi MV, Sagredou S, Vakkas L, Trafalis DT. The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries. Cancers (Basel) 2021;13:5277. [PMID: 34771441 DOI: 10.3390/cancers13215277] [Reference Citation Analysis]
7 Capaccione KM, Valiplackal JP, Huang A, Roa T, Fruauff A, Liou C, Kim E, Khurana S, Maher M, Ma H, Ngyuen P, Mak S, Dumeer S, Lala S, D'souza B, Laifer-Narin S, Desperito E, Ruzal-Shapiro C, Salvatore MM. Checkpoint Inhibitor Immune-Related Adverse Events: A Multimodality Pictorial Review. Acad Radiol 2022:S1076-6332(22)00171-4. [PMID: 35382975 DOI: 10.1016/j.acra.2022.03.007] [Reference Citation Analysis]
8 Irwin DE, Davis B, Bell JA, Galaznik A, Garcia-Ribas I. Gastrointestinal complications in patients treated with ipilimumab and nivolumab combination therapy or monotherapy. J Comp Eff Res 2019;8:81-90. [PMID: 30547675 DOI: 10.2217/cer-2018-0072] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
9 Raschi E, Gatti M, Gelsomino F, Ardizzoni A, Poluzzi E, De Ponti F. Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance. Target Oncol 2020;15:449-66. [PMID: 32725437 DOI: 10.1007/s11523-020-00738-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
10 Mazzarella L, Morganti S, Marra A, Trapani D, Tini G, Pelicci P, Curigliano G. Master protocols in immuno-oncology: do novel drugs deserve novel designs? J Immunother Cancer 2020;8:e000475. [PMID: 32238471 DOI: 10.1136/jitc-2019-000475] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
11 Sato K, Mano T, Iwata A, Toda T. Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database. J Neurooncol 2019;145:1-9. [PMID: 31452071 DOI: 10.1007/s11060-019-03273-1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 12.3] [Reference Citation Analysis]
12 Deligiorgi MV, Liapi C, Trafalis DT. Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces. Expert Opin Biol Ther 2021;21:1097-120. [PMID: 33393372 DOI: 10.1080/14712598.2021.1869211] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Durães J, Coutinho I, Mariano A, Geraldo A, Macário MC. Demyelinating disease of the central nervous system associated with Pembrolizumab treatment for metastatic melanoma. Mult Scler 2019;25:1005-8. [DOI: 10.1177/1352458518803724] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
14 Huang Z, Su W, Lu T, Wang Y, Dong Y, Qin Y, Liu D, Sun L, Jiao W. First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress. Front Pharmacol 2020;11:578091. [PMID: 33117170 DOI: 10.3389/fphar.2020.578091] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
15 Cataldi M, Manco F, Tarantino G. Steatosis, Steatohepatitis and Cancer Immunotherapy: An Intricate Story. Int J Mol Sci 2021;22:12947. [PMID: 34884762 DOI: 10.3390/ijms222312947] [Reference Citation Analysis]
16 Huynh-Le MP, Shults RC, Connor MJ, Hattangadi-Gluth JA. Adverse Events Associated With Radium-223 in Metastatic Prostate Cancer: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization. Clin Genitourin Cancer 2020;18:192-200.e2. [PMID: 31902714 DOI: 10.1016/j.clgc.2019.11.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
17 Tian Y, Abu-sbeih H, Wang Y. Immune Checkpoint Inhibitors-Induced Hepatitis. In: Naing A, Hajjar J, editors. Immunotherapy. Cham: Springer International Publishing; 2018. pp. 159-64. [DOI: 10.1007/978-3-030-02505-2_8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
18 Scotté F, Ratta R, Beuzeboc P. Side effects of immunotherapy: a constant challenge for oncologists. Curr Opin Oncol 2019;31:280-5. [PMID: 30925538 DOI: 10.1097/CCO.0000000000000541] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
19 Aggarwal P. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system. Expert Opin Drug Saf 2019;18:623-33. [PMID: 31088310 DOI: 10.1080/14740338.2019.1619693] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
20 Casarotto E, Noize P, Gouverneur A, Berdaï D, Bégaud B, Levy‐bachelot L, Molimard M. Overview of French databases available for studying anticancer drugs in real‐life setting. Fundam Clin Pharmacol 2021;35:76-85. [DOI: 10.1111/fcp.12592] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Simoes CC, Thung SN, Fiel MI, Sung MW, Schwartz ME, Ward SC. Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy. Mod Pathol 2021;34:823-33. [PMID: 32989224 DOI: 10.1038/s41379-020-00679-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 De Mello RAB, Voscaboinik R, Luciano JVP, Cremonese RV, Amaral GA, Castelo-Branco P, Antoniou G. Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives. Cancers (Basel) 2021;14:122. [PMID: 35008287 DOI: 10.3390/cancers14010122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Lin LL, Lin GF, Yang F, Chen XQ. A systematic review and meta-analysis of immune-mediated liver dysfunction in non-small cell lung cancer. Int Immunopharmacol 2020;83:106537. [PMID: 32371246 DOI: 10.1016/j.intimp.2020.106537] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
24 Hu Y, Gong J, Zhang L, Li X, Zhao B, Hai X. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system. Int Immunopharmacol. 2020;84:106601. [PMID: 32422528 DOI: 10.1016/j.intimp.2020.106601] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
25 Cutroneo PM, Isgrò V, Ientile V, Santarpia M, Ferlazzo G, Fontana A, Carrega P, Matarangolo E, Barnaba S, Spina E, Trifirò G. Safety profile of immune checkpoint inhibitors: An analysis of the Italian spontaneous reporting system database. Br J Clin Pharmacol 2021;87:527-41. [PMID: 32495965 DOI: 10.1111/bcp.14413] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]